๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 18 Guangzhou 2 Shenzhen 1 Ankang 1 Anyang 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing18 Guangzhou2 Shenzhen1 Ankang1 Anyang1
All 18 locations
Target enrolment
to

Trials with a site in Beijing

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab
NCT07810634Breast Cancer
Beijing 302 Hospital
Observational
200
Beijing
2026-09-02
Not yet open
Safety and Immunogenicity of HPV Vaccine in HIV-infected
NCT07797894HIV-infected Individuals
Beijing 302 Hospital
Phase 1/2
80
Beijing
2026-09-01
Not yet open
TEAS for Sedation During ERCP: A Multicenter Trial With Mechanistic Substudy
NCT07440342Endoscopic Retrograde Cholangiopancreatography, Conscious Sedation Adverse Event, Procedural Pain, Sedation-related Complications
Beijing 302 Hospital
Not applicable
130
Beijing
2026-09-01
Not yet open
Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis
NCT07795151Primary Biliary Cholangitis
Beijing 302 Hospital
Phase 1/2
68
Beijing
2026-08-31
Recruiting
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
NCT07637877Immunological Non-Responders in People With HIV
Beijing 302 Hospital
Phase 2
21
Beijing, Guangzhou, Shenzhen
2026-06-15
Recruiting
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
NCT07514832AML (Acute Myeloid Leukemia)
Beijing 302 Hospital
Phase 2
48
Beijing
2026-04-15
Recruiting
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
NCT07297173Relapsed Leukemia, Refractory Leukemia
Beijing 302 Hospital
Phase 1
5
Beijing
2025-12-01
Not yet open
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
NCT06556862HR+/HER2- Advanced Breast Cancer
Beijing 302 Hospital
Phase 2
155
Beijing
2025-10-01
Recruiting
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
NCT07078591Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2
50
Beijing
2025-06-20
Recruiting
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
NCT07238686Myelodysplastic Syndromes
Beijing 302 Hospital
Phase 2
40
Beijing
2025-06-20
Not yet open
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647HBV, Chronic Hepatitis b
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Recruiting
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
NCT06741722AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2
20
Beijing
2024-10-31
Recruiting
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
NCT06418594HER2-negative Breast Cancer Brain Metastases
Beijing 302 Hospital
Phase 2
30
Beijing
2024-10-10
Not yet open
Antiviral Therapy in Infants With HBV Infection
NCT06503796HBV
Beijing 302 Hospital
Phase 4
60
Beijing
2024-08
Recruiting
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
NCT06536959Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Minimal Residual Disease
Beijing 302 Hospital
Phase 2
67
Beijing
2024-07-18
Recruiting
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
NCT05224960Decompensated Cirrhosis
Beijing 302 Hospital
Phase 2
140
Lanzhou, Guangzhou, Sanya, Wuhan, Shanghai, Kashgar, Beijing
2024-06-27
Active, closed
The Treatment of PD-1 Antibody Combined With Peg-IFNฮฑ in NAs-suppressed CHB Patients
NCT06357806Chronic Hepatitis B
Beijing 302 Hospital
Not applicable
45
Beijing
2024-05-17
Recruiting
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
NCT05985863Acute-On-Chronic Liver Failure
Beijing 302 Hospital
Phase 1/2
150
Beijing
2023-09-30
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

10 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 18 studies
PhaseStudiesRecruitingShare
Phase 29850%
Phase 1/23116.7%
Not applicable2011.1%
Observational2011.1%
Phase 1115.6%
Phase 4105.6%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Beijing 302 Hospital1810
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.